|
Safety is always of paramount concern when treating patients with systemic biologic therapeutic agents that target the immune system. Reactivation or unmasking viruses has been a topic of discussion since the first anti-TNF agents entered the marketplace.
The data related to herpes zoster presented in the article below is reassuring. Additionally, it is good to note that Cimzia has demonstrated safety for pregnancy and breastfeeding, according to its label. The article below offers more insight into the efficacy and safety of this unique agent. It was most recently approved by the FDA for the treatment of adults with moderate-to-severe plaque psoriasis.
Last, data on a fixed combination topical suggest a synergistic effect with improved outcomes. As compliance is always an issue, when you can reduce application to once daily and combine agents, odds of compliance improve — and so may the treatment outcomes. Dr. Stein Gold provides additional insights into this unique formulation below.
|
